The macroenvironment in 2025 looks grim as signs of a slowdown in the economy set in. The biotech industry experienced a choppy ride in 2024, and the same is likely in store in 2025. Given the continuous need for innovative medical treatments, irrespective of the state of the economy, the biotech industry will continue to grab investors’ interest despite the inherent volatility and uncertain macroeconomic environment.M&A activity is likely to accelerate in 2025 with a change in administration and expected d ...

SAN RAFAEL, Calif., Jan. 13, 2025 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced that the company has initiated a legal action against Ascendis Pharma A/S for infringement of European patent EP 3 175 863 B1 at the Unified Patent Court (UPC) in Munich, Germany. The patent covers long-acting variants of C-Type Natriuretic Peptide (CNP). The legal action, which would result in a decision in the next 12-15 months, is based on BioMarin's belief that Ascendis' TransCon CNP investigati ...

Shares of BioMarin Pharmaceutical (BMRN) have gained 2.1% over the past four weeks to close the last trading session at $67.38, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $98.28 indicates a potential upside of 45.9%.The average comprises 25 short-term price targets ranging from a low of $65 to a high of $138, with a standard deviation of $17.42. While the lowest estimate in ...

SAN RAFAEL, Calif., Jan. 6, 2025 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Alexander Hardy, President and Chief Executive Officer of BioMarin, will present at the 43rd Annual J.P. Morgan Conference on Monday, January 13, 2024, at 9:00 am PT / 12:00 pm ET, in San Francisco, California. An audio webcast of the presentation will be available live. You can access the webcast at: https://investors.biomarin.com/. An archived version of the remarks will also be available thro ...

Investors in BioMarin Pharmaceutical Inc. (BMRN) need to pay close attention to the stock based on moves in the options market lately. That is because the Jan 17, 2025 $40 Call had some of the highest implied volatility of all equity options today.What is Implied Volatility?Implied volatility shows how much movement the market is expecting in the future. Options with high levels of implied volatility suggest that investors in the underlying stocks are expecting a big move in one direction or the other. It c ...

It doesn't matter your age or experience: taking full advantage of the stock market and investing with confidence are common goals for all investors. Luckily, Zacks Premium offers several different ways to do both.The popular research service can help you become a smarter, more self-assured investor, giving you access to daily updates of the Zacks Rank and Zacks Industry Rank, the Zacks #1 Rank List, Equity Research reports, and Premium stock screens.Zacks Premium includes access to the Zacks Style Scores a ...

文章核心观点 - BioMarin Pharmaceutical (BMRN) 在2024年第三季度的财报中表现强劲，收入和利润均超出预期，主要得益于Voxzogo等产品的强劲销售 - 尽管如此，公司股价在过去一个月下跌了约1.9%，表现逊于S&P 500指数 - 分析师对公司未来表现的预期有所下调，但公司仍保持Zacks Rank 3 (Hold) 评级 [1][2][3][10][11][12][13][15] Q3 财报表现 - 调整后每股收益为91美分，超出Zacks共识预期的78美分，同比增长98%，主要由销售额增长推动，部分被运营费用上升所抵消 [2] - 总收入为7.46亿美元，同比增长28%（按报告基础）和32%（按固定汇率基础），超出Zacks共识预期的7.07亿美元，主要由Voxzogo的强劲销售推动 [3] 产品销售情况 - 产品收入总计7.339亿美元，同比增长29%，主要由Voxzogo、Naglazyme、Palynziq和Aldurazyme的销售增长推动，部分被Kuvan销售额下降所抵消 [4] - Voxzogo销售额为1.9亿美元，同比增长54%，主要由美国标签扩展至更年轻的年龄组（5岁以下）推动，截至第三季度末，全球有超过3,800名儿童（包括许多婴儿）正在接受Voxzogo治疗 [5] - Vimizim销售额为1.78亿美元，同比增长12%，但未达到Zacks共识预期和模型预期 [6] - Palynziq销售额为9,100万美元，同比增长15%，超出Zacks共识预期和模型预期 [7] - Naglazyme销售额为1.32亿美元，同比增长21%，主要由需求增加和订单时间的有利影响推动 [7] - Roctavian销售额为700万美元，同比增长600%，主要由公司在三个优先国家（美国、德国和意大利）的策略调整推动 [8] - Kuvan销售额为2,800万美元，同比下降35%，主要由仿制药竞争影响 [9] - Aldurazyme销售额为7,100万美元，同比增长407%，主要由向Sanofi的订单履行时间有利影响 [9] 2024年指引 - 公司上调了2024年财务指引，预计总收入在27.90-28.25亿美元之间，高于之前的27.50-28.25亿美元指引 [10] - 调整后营业利润率预计在26.5%-27.5%之间，高于之前的26-27%指引 [10] - 调整后每股收益预计在3.25-3.35美元之间，高于之前的3.10-3.25美元指引 [11] 分析师预期 - 过去一个月，分析师对BioMarin的预期有所下调，共识预期下降了8.89% [12][13] VGM 评分 - BioMarin在Growth Score上获得A评级，在Momentum Score上获得C评级，在Value Score上获得B评级，总体VGM Score为A [14]

BioMarin Pharmaceutical TodayBMRNBioMarin Pharmaceutical$63.44 +0.88 (+1.41%) 52-Week Range$61.15▼$99.56P/E Ratio37.99Price Target$94.20Add to WatchlistBioMarin Pharmaceutical NASDAQ: BMRN has been a rough investment for a long time. Over the past 10 years, shares have provided a total return of -28%. However, Wall Street analysts have consistently given this stock price targets that are much higher than its trading price. They see more fundamental value in the company than the market will give it credit f ...

If you like what you have just read and want to receive at least 4 exclusive stock tips every week focused on Pharma, Biotech and Healthcare, then join me at my marketplace channel, Haggerston BioHealth . Invest alongside the model portfolio or simply access the investment bank-grade financial models and research. I hope to see you there.I last covered BioMarin (NASDAQ: BMRN ) in a note for Seeking Alpha back in June last year, just ahead of the Prescription Drug User fee Act ("PDUFA") date for its hemophil ...

It doesn't matter your age or experience: taking full advantage of the stock market and investing with confidence are common goals for all investors. Luckily, Zacks Premium offers several different ways to do both.Featuring daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, the research service can help you become a smarter, more self-assured investor.Zacks Premium includes access to the Zacks Style Scores as we ...